Apixaban Use Guidelines

Primary Indications

The American Heart Association recommends apixaban for patients with nonvalvular atrial fibrillation who have at least one additional stroke risk factor, with a standard dosing of 5 mg twice daily for most patients, and a reduced dose of 2.5 mg twice daily for patients who meet at least 2 of the following 3 criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, with a strength of evidence of high quality 1, 2, 3, 4
The European Society of Cardiology notes that apixaban demonstrated a 21% reduction in stroke or systemic embolism compared to warfarin, a 31% reduction in major bleeding, and an 11% reduction in all-cause mortality, in the ARISTOTLE trial, with a strength of evidence of high quality 4, 2

The National Kidney Foundation guidelines state that apixaban can be used in patients with severe renal impairment, with a creatinine clearance of 15-30 mL/min, unlike dabigatran which is contraindicated below a creatinine clearance of 30 mL/min, with a strength of evidence of moderate quality 1, 2
The American College of Cardiology recommends that for end-stage renal disease on hemodialysis, apixaban should be started with 5 mg twice daily, reducing to 2.5 mg twice daily only if age ≥80 years or body weight ≤60 kg, with a strength of evidence of low quality 2

The American College of Chest Physicians recommends apixaban for prophylaxis of deep vein thrombosis following hip or knee replacement surgery, with a dosing of 10 mg twice daily for 7 days, then 5 mg twice daily for continued treatment, with a strength of evidence of high quality 5
The European Society of Cardiology notes that apixaban is indicated for treatment of acute deep vein thrombosis, treatment of acute pulmonary embolism, and reduction of recurrent deep vein thrombosis and pulmonary embolism risk after initial therapy, with a strength of evidence of high quality 2, 1

The American Heart Association states that apixaban should not be used in patients with mechanical prosthetic heart valves or clinically significant mitral stenosis, with a strength of evidence of high quality 1, 2
The European Heart Journal guidelines note that apixaban is preferred over warfarin in patients with elevated bleeding risk, as it reduces major bleeding by 31% and intracranial hemorrhage by approximately 58% compared to warfarin, with a strength of evidence of high quality 4, 2, 6

The American College of Cardiology recommends that apixaban should be strongly considered in patients with advanced age, renal impairment, high bleeding risk, or poor warfarin control, with a strength of evidence of moderate quality 6, 4, 1, 5
The European Society of Cardiology notes that no routine coagulation monitoring is required for apixaban, but renal function should be assessed before initiation and at least annually, with a strength of evidence of low quality 2, 1, 3